scholarly journals Prognostic value of preoperative serum CEA level compared to clinical staging: Ii. Stomach cancer

1982 ◽  
Vol 45 (5) ◽  
pp. 718-727 ◽  
Author(s):  
H J Staab ◽  
F A Anderer ◽  
T Brümmendorf ◽  
A Hornung ◽  
R Fischer
Keyword(s):  
Stomach Cancer ◽  
Prognostic Value ◽  
Clinical Staging ◽  
Preoperative Serum ◽  
Serum Cea

scholarly journals Prognostic value of preoperative serum CEA level compared to clinical staging. I. Colorectal carcinoma

1981 ◽  
Vol 44 (5) ◽  
pp. 652-662 ◽  
Author(s):  
H J Staab ◽  
F A Anderer ◽  
T Brümmendorf ◽  
E Stumpf ◽  
R Fischer
Keyword(s):  
Colorectal Carcinoma ◽  
Prognostic Value ◽  
Clinical Staging ◽  
Preoperative Serum ◽  
Serum Cea

Carcinoembryonic Antigen in Gynecologic Cancers. Immunohistochemical Localization and Serum Levels

1983 ◽  
Vol 69 (1) ◽  
pp. 23-30 ◽  
Author(s):  
Józef Kula ◽  
Antonina Harlozinska ◽  
Roman Richter ◽  
Zygmunt Albert ◽  
Józef Sward ◽  
...  
Keyword(s):  
Carcinoembryonic Antigen ◽  
Genital Tract ◽  
Female Genital Tract ◽  
Serum Levels ◽  
Immunohistochemical Localization ◽  
Double Immunodiffusion ◽  
Preoperative Serum ◽  
Serum Cea ◽  
Different Content ◽  
Female Genital

The presence of carcinoembryonic antigen (CEA)-dependent fluorescence was observed in almost 89% of female genital tract cancers irrespective of their histologic type. Anti-CEA serum was free of antibody to normal cross-reacting antigen. The high percentage of positive fluorescence tests did not correlate with the preoperative serum CEA levels. Double immunodiffusion tests showed different content of CEA and normal cross-reacting antigen in individual specimens of genital tract cancers.

Volume-Based Consolidation-to-Tumor Ratio Is a Useful Predictor for Postoperative Upstaging in Stage I and II Lung Adenocarcinomas

2019 ◽  
Author(s):  
Masanori Shimomura ◽  
Masashi Iwasaki ◽  
Shunta Ishihara ◽  
Masayoshi Inoue
Keyword(s):  
Mediastinal Lymph Node ◽  
Clinical Stage ◽  
Growth Factor Receptor ◽  
Standardized Uptake Value ◽  
Stage I ◽  
Clinical Staging ◽  
Tumor Diameter ◽  
Preoperative Serum ◽  
Serum Carcinoembryonic Antigen ◽  
Lung Adenocarcinomas

Background We investigated the postoperative upstaging of stage I and II lung adenocarcinoma patients to identify useful predictors for accurate staging. Methods We retrospectively reviewed data from 80 consecutive patients undergoing lobectomy and mediastinal lymph node dissection for clinical stage I and II lung adenocarcinomas. We evaluated clinical variables, including the preoperative serum carcinoembryonic antigen (CEA), tumor diameter, consolidation-to-tumor ratio (CTR), maximum standardized uptake value (SUVmax) on FDG- PET, expression of epithelial growth factor receptor mutations, and pathological invasion to the pleura (pl), lymph duct (ly), and vein (v). Results Eleven patients (13.8%) showed postoperative upstaging. Three cases had pN1 migrating from cN0, four cases had pN2 from cN0, and four cases showed malignant pleural effusion. The CEA level and CTR were significantly higher in the upstaging group. The tumors in the upstaging group showed more frequent pathological invasion to the visceral pleura and vein. In patients with 3 cm or smaller consolidation, two-dimensional (2D)-CTR and volume-based CTR were independent predictors of upstaging. Conclusions Volume-based CTR could be a useful predictor for accurate clinical staging in stage I and II adenocarcinoma patients in addition to consolidation size, serum CEA level, and 2D-CTR. Both volume-based and 2D-CTRs might be especially useful in T1 diseases.

scholarly journals Preoperative Serum Carcinoembryonic Antigen as a Marker for Predicting the Outcome of Three Cancers

2017 ◽  
Vol 9 ◽  
pp. 1179299X1769014 ◽  
Author(s):  
Jingzhu Nan ◽  
Juan Li ◽  
Xiujuan Li ◽  
Guanghong Guo ◽  
Xinyu Wen ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Carcinoembryonic Antigen ◽  
Youden Index ◽  
Rank Test ◽  
Prognostic Information ◽  
Treatment Implementation ◽  
Preoperative Serum ◽  
Serum Carcinoembryonic Antigen ◽  
Serum Cea

Background: Serum levels of carcinoembryonic antigen (CEA) are associated with a variety of tumors. Objective: This study evaluated the prognostic value of pretreatment serum CEA levels in predicting the outcomes of multiple tumors subjected to treatment. Methods: Prior to therapy, serum samples from 71 prostate, 46 breast, 77 gastric, and 31 pancreatic cancer patients were collected to examine serum CEA levels. The cutoff value for CEA was set as determined by the maximum Youden index. The data were analyzed by the Kaplan-Meier curves generated by the log-rank test and Cox multivariate analysis. Results: The overall survival rate for all the patients was 71.11%. The 3-year survival rate of patients with prostate, breast, gastric, and pancreatic cancers was 81.69%, 95.65%, 54.55%, and 51.61%, respectively. The 3-year survival rate showed significant statistical differences between patients with serum CEA levels <2.885 µg/L and those with serum CEA levels ⩾2.885 µg/L ( P < .001). The statistical differences of the 3-year survival rate also existed in the men ( P = .010) or women group ( P < .001), as well as in the 3 different types of cancer, which include breast cancer ( P = .025), gastric cancer ( P = .001), and pancreatic cancer ( P = .047). Conclusions: Serum CEA levels can provide additional prognostic information and may be useful in treatment implementation for patients with breast, gastric, or pancreatic cancer.

The prognostic value of serum IL-6 and YKL-40 in colorectal cancer patients before liver resection.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15078-e15078
Author(s):  
Mathias Holsey Gramkow ◽  
Reetta Peltonen ◽  
Christian Dehlendorff ◽  
Pia J. Osterlund ◽  
Julia S. Johansen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Multivariate Analysis ◽  
Liver Resection ◽  
Cox Regression ◽  
Univariate Analysis ◽  
Elevated Serum ◽  
Disease Free Survival ◽  
Markers Of Inflammation ◽  
Preoperative Serum ◽  
Serum Cea

e15078 Background: IL-6 and YKL-40, markers of inflammation and cancer growth, are high in serum in patients with colorectal cancer (CRC) and associated with shorter overall survival (OS). We hypothesized that preoperative serum IL-6, YKL-40 and CEA are associated with disease free survival (DFS) and OS in patients with metastatic (mCRC) treated with liver resection. Methods: 457 patients (male/female: 267 (58%)/190 (42%), median age 65 [IQR: 58-71]) diagnosed with mCRC who underwent liver resection were included between March 1998 and February 2013. Preoperative serum samples were collected and stored at -80°C until analysis. Serum IL-6 (R&D Systems, UK) and YKL-40 (Quidel, USA) were determined by ELISA. For DFS and OS we estimated crude and adjusted hazard ratios (HR) and corresponding 95% confidence intervals (CIs) with Cox regression for each biomarker separately. The biomarkers were included as log2-transformed continuous variables and adjustment included mutual adjustment between the biomarkers in addition to adjusting for sex and age. Results: The median (IQR) preoperative biomarker levels were: IL-6 (3.5 pg/ml, 2.1-6.1), YKL-40 (75 ng/ml, 48-127) and CEA (5.2 kU/L, 2.6-18.8). Univariate analysis showed that high serum IL-6 and YKL-40 were associated with shorter DFS (IL-6: HR = 1.18, 1.06-1.31, p < 0.01; YKL-40: HR = 1.19, 1.08-1.32, p < 0.01). Serum CEA was not (p = 0.80). Multivariate analysis (all biomarkers) showed that high IL-6 was associated with shorter DFS (HR = 1.15, 1.02-1.29, p = 0.02), whereas YKL-40 (p = 0.08) and CEA (p = 0.51) were not. Univariate analysis showed that high preoperative serum IL-6 and YKL-40 were associated with shorter OS (IL-6: HR = 1.16, 1.03-1.29, p = 0.01; YKL-40: HR = 1.27, 1.14-1.42, p < 0.01). Serum CEA was not associated with OS (p = 0.16). Multivariate analysis (all biomarkers) showed that high YKL-40 was associated with shorter OS (HR = 1.19, 1.05-1.34, p = 0.01), whereas IL-6 (p = 0.25) and CEA (p = 0.26) were not. Patients with elevated serum levels of all 3 biomarkers had the shortest OS (HR = 2.12; 1.29-3.50, p < 0.01). Conclusions: Serum IL-6 and YKL-40 determined before liver resection may be valuable prognostic biomarkers in patients with metastatic CRC.

Sign in / Sign up

Export Citation Format

Share Document